Elba Medina's Avatar

Elba Medina

@elbaonelida.bsky.social

Nephrologist in Mexico, HGM, #NSMC intership 2024 #NephSky #MedSky #LatinSky #HMSky #Kidneydisease #sunrise #NephJC

1,105 Followers  |  3,965 Following  |  28 Posts  |  Joined: 16.11.2024  |  2.025

Latest posts by elbaonelida.bsky.social on Bluesky


Post image

To say it took a while is an understatement, because #NephJC has been around for 11 years (and still counting)...

πŸ₯ We opened an Instagram account, so if you're around, can follow and interact πŸ‘£πŸ’ž

#NephSky #Medsky

31.01.2026 16:58 β€” πŸ‘ 11    πŸ” 6    πŸ’¬ 0    πŸ“Œ 0
Post image

πŸ“£ WCN’26 Social Media Team Kickoff Meeting
We’re delighted to welcome our new team members πŸ™ŒπŸΌ
Meet the people behind the content:
πŸ”— theisn.org/wcn/media/so...
#ISNWCN

16.01.2026 13:39 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 1
Post image Post image Post image Post image

πŸ”¬ Stay on top of the evidence

At #ISNWCN, the HIT & LBCT sessions spotlight the clinical trials that matter most for patient care, from late-breaking results to ongoing studies.

β€œAs a community, this helps us stay on top of the evidence base,” says Adeera Levin. Read more: lite.spr.ly/6003OtWX

13.01.2026 17:37 β€” πŸ‘ 2    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0
Post image

Meet the #ISNWCN Social Media Team! πŸŽ‰ A group of health pros bringing you live updates from WCN'26 in Yokohama, πŸ‡―πŸ‡΅, with scientific session coverage, quizzes, interviews, visual abstracts, workshops & more! Get ready for engaging content! lite.spr.ly/6008OsHw

12.01.2026 14:31 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

#Dapagliflozin in CKD Patients with #Fabry Disease

#VisualAbstract by Elba Medina

https://www.kireports.org/article/S2468-0249(25)00760-0/fulltext

14.01.2026 00:00 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Preview
Top Stories in Nephrology 2025 β€” NephJC 2025 was rich in successful stories. Here are the top 10 that impressed our audience.

It's 2026!πŸŽ‰
We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST.
Join us on TWITTER (it will always be Twitter to us).
Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down.
www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

03.01.2026 19:03 β€” πŸ‘ 14    πŸ” 13    πŸ’¬ 1    πŸ“Œ 3
Post image

Did we (meaning "you" of course, because you voted) get them right? Is there something missing or is the order wrong? #NephJC #TopTenStories2025
Come discuss with an international cadre of nephrologists & other interested parties on 1/6/26 at 9 pm EST on #Twitter

03.01.2026 19:06 β€” πŸ‘ 5    πŸ” 7    πŸ’¬ 0    πŸ“Œ 0
Post image

✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award

πŸ‘‡Here's a reminder of previous winners #Nephsky

πŸ“ŒYou can nominate worthy individuals/ initiatives by using the hashtag or by using the form

www.nephjc.com/news/2026/1/...

08.01.2026 16:04 β€” πŸ‘ 9    πŸ” 6    πŸ’¬ 0    πŸ“Œ 0

The future of nephrology

18.12.2025 06:34 β€” πŸ‘ 2    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Post image

22/πŸŽ₯Functional imaging studies have enhanced our understanding of physiology & pathology. πŸ“Έ
However, most techniques are limited by variability in platforms, protocols, and image analysis. Standardization is crucial to unlock their full potential!🀳

18.12.2025 04:15 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0

β€œNuestras cicatrices nos hacen saber que nuestro pasado fue real”
Jane Austen

18.12.2025 05:20 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

10/ Evaluating tubular function through dynamic physiological stress tests is essential for a comprehensive understanding of kidney function. e.g the furosemide stress test assesses renal tubular integrity.

18.12.2025 04:15 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
https://www.kireportscommunity.org/post/towards-new-ways-of-assessing-kidney-function-where-to-look-to-improve

https://www.kireportscommunity.org/post/towards-new-ways-of-assessing-kidney-function-where-to-look-to-improve

5/ Read the executive summary and watch the meeting video for more information. πŸ”₯πŸ”₯Start with the majors' key research questionsπŸ”₯πŸ”₯

18.12.2025 04:15 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Post image

Congratulations to Leo Riella and team reporting physiology aspects from the first porcine kidney transplanted to a human. Happy to have contributed findings on pig renin and the renin-angiotensin system. @natcomms.nature.com @nu-nephrology.bsky.social @nufeinbergmed.bsky.social
rdcu.be/eIyQt

29.09.2025 21:14 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Thanks to @asnpublications.bsky.social for highlighting our feature on a new syndrome of renal tubular alkalosis! www.kidneynews.org/view/journal... @nu-nephrology.bsky.social @nufeinbergmed.bsky.social

16.10.2025 15:28 β€” πŸ‘ 5    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0

Do we continue to measure kidney function with tools from the last century?
The workshop for Kidney Function Assessment of @NIDDKgov proposes a revolution: Go beyond Creatinine & eGFR!
πŸ’₯Check out this blog & Skytorial !πŸ§΅πŸ‘‡
@kireports.bsky.social
πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡
www.kireportscommunity.org/post/towards...

18.12.2025 04:33 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

1/Hey #NephTwitter! Welcome to a πŸ†• #Skytorial brought to you by @kireports.bsky.social @isnkidneycare.bsky.social Our author is @elbaonelida.bsky.social nephrologist at Hospital General de Mexico πŸ‡²πŸ‡½ @hgm_nefrologia. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!

18.12.2025 04:15 β€” πŸ‘ 8    πŸ” 2    πŸ’¬ 1    πŸ“Œ 1
Preview
LIBERATE-D: The Visual Abstract β€” NephJC In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...

The LIBERATE-D VA by
@sejalplakhani.bsky.social

Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky

www.nephjc.com/news/liberateva

15.12.2025 14:42 β€” πŸ‘ 8    πŸ” 9    πŸ’¬ 0    πŸ“Œ 0
Preview
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D β€” NephJC This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!πŸ₯³
How soon should we withhold dialysis in AKI?
We're discussing the LIBERATE-D trial #NephSky
This one might just change your mind 🧠🧠
Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki

15.12.2025 14:40 β€” πŸ‘ 12    πŸ” 12    πŸ’¬ 2    πŸ“Œ 1
Preview
LIBERATE-D: El Resumen Visual β€” NephJC En pacientes con lesiΓ³n renal aguda en diΓ‘lisis, se evaluΓ³ si una estrategia mΓ‘s conservadora impacta en la recuperaciΓ³n renal. ΒΏSerΓ‘ que menos es mΓ‘s? Únete a la discusiΓ³n del ensayo clΓ­nico LIBERATE...

Gracias! @dramiliflores.bsky.social #NephSky
LIBERATE-D: El Resumen Visual β€” #NephJC

www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

15.12.2025 14:56 β€” πŸ‘ 13    πŸ” 6    πŸ’¬ 1    πŸ“Œ 0
Preview
NephJC Shorts: Hypertension and The Extreme Elderly β€” NephJC The NephJC shorts version of the Hypertension medication step-down in a nursing home population from NEJM

πŸ†• #NephJCshort by @brianrifkin.bsky.social

RETREAT-FRAIL- pragmatic RCT: is less BP medication worse in octogenarians?

www.nephjc.com/news/hyperte...

04.12.2025 09:12 β€” πŸ‘ 13    πŸ” 7    πŸ’¬ 2    πŸ“Œ 1
Post image

Kidney Tertiary #LymphoidTissues and Poor #Immunosuppressive Response in #IgANephropathy #IgAN

#VisualAbstract by Elba Medina

https://www.kireports.org/article/S2468-0249(25)00677-1/fulltext

03.12.2025 14:00 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Preview
Dialysis deferred, logic recycled: BICAR ICU2 β€” NephJC NephJC short on BICAR-ICU2

#NephJCshort on BICAR-ICU2 #Medsky #Nephsky

✍️ By @nephroseeker.medsky.social

🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors

www.nephjc.com/news/2025/10...

25.11.2025 00:19 β€” πŸ‘ 17    πŸ” 8    πŸ’¬ 4    πŸ“Œ 1
Post image

T3f: #NephJC

Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).

Do you think either has the advantage?

19.11.2025 02:41 β€” πŸ‘ 12    πŸ” 7    πŸ’¬ 2    πŸ“Œ 0
Post image

T3d: #NephJC

In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.

In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.

19.11.2025 02:39 β€” πŸ‘ 5    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Post image

T3c: #NephJC

The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.

19.11.2025 02:38 β€” πŸ‘ 4    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Post image

T2c: #NephJC

1Β° Endpoint
At week 36- πŸ—“οΈ

πŸ“‰Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%

πŸ”»Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%

19.11.2025 02:31 β€” πŸ‘ 5    πŸ” 2    πŸ’¬ 2    πŸ“Œ 0
Post image

T0h: #NephJC

Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.

www.kidneynews.org/v...

19.11.2025 02:15 β€” πŸ‘ 6    πŸ” 4    πŸ’¬ 1    πŸ“Œ 0
Post image

T0i: #NephJC

Mechanistic lead-in came from the JANUS ph2 study (N=16):

πŸ‘‰ dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24
πŸ‘‰maintained through week 72
πŸ‘ concurrent proteinuria improvement and preserved eGFR
pubmed.ncbi.nlm.nih....

19.11.2025 02:17 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Post image

T0j: #NephJC

The ORIGIN phase 2b trial

πŸ‘₯ 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi

πŸ’‰ Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
βš™οΈ a mean eGFR benefit of +5.8 mL/min/1.73 mΒ²

pubmed.ncbi.nlm.nih....

19.11.2025 02:18 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 1    πŸ“Œ 0

@elbaonelida is following 18 prominent accounts